WHITE PAPER
Mitigating Trial Risk in ALS Clinical Development
Key strategies for overcoming common hurdles in ALS research
Jan 18, 2022

The development of new treatments has been slow, with only two approved disease-modifying drugs that offer limited benefit. But significant advances in immuno-neurology have set the stage for promising novel treatments that could offer hope to these families and change the course of this disease.

IQVIA has been at the leading edge of this research. Our experts have identified key strategies for overcoming common hurdles and strengthening patient centricity in ALS research, and for driving new progress that can benefit ALS patients across the globe

Contact Us